Literature DB >> 30416790

Contemporary outcomes of surgical management of complex thoracic infections.

Ian C Bostock1, Fariha Sheikh1, Timothy M Millington1,2, David J Finley1,2, Joseph D Phillips1,2.   

Abstract

BACKGROUND: Surgery plays an important role in the management of complex thoracic infections (CTIs). We aimed to describe the contemporary surgical outcomes of CTIs.
METHODS: The 2014-2017 National Surgical Quality Improvement Program (NSQIP) database was queried for patients with the following procedures: bilobectomy, decortication, lung release, lobectomy, thoracoscopic lobectomy, thoracoscopic pleurodesis, thoracoscopic wedge resection, thoracoscopic biopsy, thoracoscopy, thoracotomy, thoracotomy with wedge resection, thoracotomy with decortication, and thoracotomy with lobectomy. Patients were classified into: drainage procedures (DP) and lung resection (LR). Descriptive statistics and univariate/multivariate analysis were executed. A P value <0.05 was considered significant.
RESULTS: A total of 1,275 patients (30.3%) underwent surgical management for a CTI. Nine hundred and seven patients (71.1%) underwent a DP, and 368 patients (28.9%) underwent a LR. A thoracic surgeon performed 64% and 79% of cases in the DP and LR groups, respectively. On univariate analysis, the patients in the LR group were less likely to be male, diabetic, active smokers, dyspneic on exertion, hypertensive, malnourished, or American Society of Anesthesiologist (ASA) >3. There was no difference in overall postoperative complications, re-intubation, or reoperation between groups. The patients in the LR group were less likely to develop sepsis or respiratory failure. There was no difference in 30-day mortality between groups (5.3% vs. 3.8%, P=0.26). The total length of stay was 13.82±10.17 and 8.7±15.05 days, in the DP and LR groups, respectively (P=0.001). Multivariate analysis revealed increased risk of 30-day mortality was associated with age, preoperative steroid use, renal failure, leukocytosis, pulmonary embolism, and sepsis.
CONCLUSIONS: CTI's are a common indication for thoracic surgical management. This contemporary, national sampling demonstrates that approximately one third of identified cases were associated with a LR. These cases demonstrated a comparable morbidity and mortality with surgical DP, but shorter hospital stays. To aid in the management of these complex disease processes, early consultation of a multidisciplinary management service for these patients should be considered. Furthermore, the appropriate use of LR for infectious etiologies may lead to safer postoperative outcomes than previously thought.

Entities:  

Keywords:  Pleural infection; decortication; empyema; lung resection; thoracic surgery

Year:  2018        PMID: 30416790      PMCID: PMC6196200          DOI: 10.21037/jtd.2018.08.43

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  19 in total

1.  [A study of relapse/recurrence cases after surgical treatment for patients with pulmonary nontuberculous mycobacteriosis].

Authors:  Katsuo Yamada; Tomoshi Sugiyama; Ayuko Yasuda; Yukio Seki; Mariko Hasegawa; Yuuta Hayashi; Osamu Tarumi; Taku Nakagawa; Noritaka Yamada; Kenji Ogawa
Journal:  Kekkaku       Date:  2013-05

Review 2.  Surgery and pleuro-pulmonary tuberculosis: a scientific literature review.

Authors:  Dragan Subotic; Piotr Yablonskiy; Giorgia Sulis; Ioan Cordos; Danail Petrov; Rosella Centis; Lia D'Ambrosio; Giovanni Sotgiu; Giovanni Battista Migliori
Journal:  J Thorac Dis       Date:  2016-07       Impact factor: 2.895

3.  Randomised controlled trial of intrapleural streptokinase in community acquired pleural infection.

Authors:  R J Davies; Z C Traill; F V Gleeson
Journal:  Thorax       Date:  1997-05       Impact factor: 9.139

4.  A double blind randomized cross over trial comparing rate of decortication and efficacy of intrapleural instillation of alteplase vs placebo in patients with empyemas and complicated parapneumonic effusions.

Authors:  G Thommi; J C Shehan; K L Robison; M Christensen; L A Backemeyer; M T McLeay
Journal:  Respir Med       Date:  2012-03-06       Impact factor: 3.415

Review 5.  The approach to the patient with a parapneumonic effusion.

Authors:  John M Wrightson; Robert J O Davies
Journal:  Semin Respir Crit Care Med       Date:  2011-01-06       Impact factor: 3.119

6.  Surgical treatment of non-tuberculous mycobacterial lung disease: strike in time.

Authors:  J van Ingen; A F T M Verhagen; P N R Dekhuijzen; D van Soolingen; C Magis-Escurra; M J Boeree; W C M de Lange
Journal:  Int J Tuberc Lung Dis       Date:  2010-01       Impact factor: 2.373

Review 7.  Parapneumonic pleural effusion and empyema.

Authors:  Coenraad F N Koegelenberg; Andreas H Diacon; Chris T Bolliger
Journal:  Respiration       Date:  2008-02-15       Impact factor: 3.580

8.  A steady increase in nontuberculous mycobacteriosis mortality and estimated prevalence in Japan.

Authors:  Kozo Morimoto; Kazuro Iwai; Kazuhiro Uchimura; Masao Okumura; Takashi Yoshiyama; Kozo Yoshimori; Hideo Ogata; Atsuyuki Kurashima; Akihiko Gemma; Shoji Kudoh
Journal:  Ann Am Thorac Soc       Date:  2014-01

9.  Intrapleural streptokinase for empyema and complicated parapneumonic effusions.

Authors:  Andreas H Diacon; Johan Theron; Macé M Schuurmans; Bernard W Van de Wal; Chris T Bolliger
Journal:  Am J Respir Crit Care Med       Date:  2004-03-24       Impact factor: 21.405

10.  U.K. Controlled trial of intrapleural streptokinase for pleural infection.

Authors:  Nicholas A Maskell; Christopher W H Davies; Andrew J Nunn; Emma L Hedley; Fergus V Gleeson; Robert Miller; Rhian Gabe; Glyn L Rees; Timothy E A Peto; Mark A Woodhead; Donald J Lane; Janet H Darbyshire; Robert J O Davies
Journal:  N Engl J Med       Date:  2005-03-03       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.